Hung leads the cross-functional activities among CMC groups at Life Edit, ElevateBio and external CDMOs to help drive tech transfer, process development, and manufacturing of Life Edit gene editing and base editing assets as well as provide program management support to other programs. He has over 10 years of combined academic and industry experience in the cell and gene therapy field.

Prior to Life Edit, Hung spent four years at Fujifilm Diosynth Biotechnologies where he held various roles from technical project lead to program design/CMC strategy, covering customer programs across all phases of development and for a wide range of therapeutic modalities including biologics, viral vaccine and gene therapy.

Hung received his PhD in Biomedical Engineering from Duke University. His graduate and postdoc research focused on developing cell and gene therapies for cardiac arrhythmic disorders.